Consun Pharmaceutical Group Limited (FRA:C1P)
Germany
· Delayed Price · Currency is EUR 1.190
+0.260 (27.96%)
Last updated: May 13, 2025
FRA:C1P Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 2,967 | 2,590 | 2,340 | 2,045 | 1,753 | Upgrade
|
| Revenue Growth (YoY) | 14.56% | 10.71% | 14.43% | 16.65% | 1.42% | Upgrade
|
| Cost of Revenue | 725.13 | 668.44 | 576.74 | 517.32 | 431.16 | Upgrade
|
| Gross Profit | 2,242 | 1,922 | 1,763 | 1,527 | 1,322 | Upgrade
|
| Selling, General & Admin | 1,293 | 1,168 | 1,094 | 900 | 746 | Upgrade
|
| Other Operating Expenses | -17.55 | -59.45 | -14.47 | -14.8 | -3.82 | Upgrade
|
| Operating Expenses | 1,267 | 1,096 | 1,048 | 867.15 | 771.54 | Upgrade
|
| Operating Income | 974.99 | 825.92 | 715.41 | 660.18 | 550.13 | Upgrade
|
| Interest Expense | -24.89 | -21.26 | -10.93 | -12.91 | -21.4 | Upgrade
|
| Interest & Investment Income | 88.3 | 68.92 | 52.41 | 39.25 | 27.89 | Upgrade
|
| Earnings From Equity Investments | -0.07 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -17.88 | -9.03 | -9.28 | 11.33 | 27.37 | Upgrade
|
| EBT Excluding Unusual Items | 1,020 | 864.55 | 747.61 | 697.85 | 583.98 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.35 | -0.85 | -1.22 | -1.99 | -0.24 | Upgrade
|
| Pretax Income | 1,020 | 863.7 | 746.39 | 695.86 | 583.74 | Upgrade
|
| Income Tax Expense | 102.73 | 77.15 | 62.7 | 108.74 | 101.99 | Upgrade
|
| Earnings From Continuing Operations | 917.37 | 786.55 | 683.7 | 587.12 | 481.74 | Upgrade
|
| Minority Interest in Earnings | -6.92 | -2.02 | -0.79 | 3.06 | 17.05 | Upgrade
|
| Net Income | 910.46 | 784.53 | 682.91 | 590.17 | 498.79 | Upgrade
|
| Net Income to Common | 910.46 | 784.53 | 682.91 | 590.17 | 498.79 | Upgrade
|
| Net Income Growth | 16.05% | 14.88% | 15.71% | 18.32% | 524.89% | Upgrade
|
| Shares Outstanding (Basic) | 821 | 791 | 791 | 802 | 817 | Upgrade
|
| Shares Outstanding (Diluted) | 832 | 799 | 792 | 805 | 817 | Upgrade
|
| Shares Change (YoY) | 4.12% | 0.91% | -1.58% | -1.54% | -4.35% | Upgrade
|
| EPS (Basic) | 1.11 | 0.99 | 0.86 | 0.74 | 0.61 | Upgrade
|
| EPS (Diluted) | 1.09 | 0.98 | 0.86 | 0.73 | 0.61 | Upgrade
|
| EPS Growth | 11.22% | 13.95% | 17.81% | 19.67% | 577.78% | Upgrade
|
| Free Cash Flow | 977.99 | 766.41 | 896.09 | 627.29 | 818.36 | Upgrade
|
| Free Cash Flow Per Share | 1.18 | 0.96 | 1.13 | 0.78 | 1.00 | Upgrade
|
| Dividend Per Share | 0.564 | 0.408 | 0.265 | 0.244 | 0.236 | Upgrade
|
| Dividend Growth | 38.03% | 53.92% | 8.58% | 3.66% | 31.87% | Upgrade
|
| Gross Margin | 75.56% | 74.19% | 75.35% | 74.70% | 75.40% | Upgrade
|
| Operating Margin | 32.86% | 31.89% | 30.58% | 32.29% | 31.39% | Upgrade
|
| Profit Margin | 30.68% | 30.29% | 29.19% | 28.86% | 28.46% | Upgrade
|
| Free Cash Flow Margin | 32.96% | 29.59% | 38.30% | 30.68% | 46.69% | Upgrade
|
| EBITDA | 1,032 | 897.51 | 785.89 | 728.71 | 618.79 | Upgrade
|
| EBITDA Margin | 34.77% | 34.65% | 33.59% | 35.64% | 35.30% | Upgrade
|
| D&A For EBITDA | 56.73 | 71.58 | 70.48 | 68.53 | 68.66 | Upgrade
|
| EBIT | 974.99 | 825.92 | 715.41 | 660.18 | 550.13 | Upgrade
|
| EBIT Margin | 32.86% | 31.89% | 30.58% | 32.29% | 31.39% | Upgrade
|
| Effective Tax Rate | 10.07% | 8.93% | 8.40% | 15.63% | 17.47% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.